CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE EQUITY AND SHAREHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Performance-Based Restricted Stock Units (PSUs)	Leveraged Stock Units (LSUs)	Cumulative-effect adjustment from adoption of ASC 2020-06	Class A Common Stock	Class A Common Stock Performance-Based Restricted Stock Units (PSUs)	Class A Common Stock Leveraged Stock Units (LSUs)	Additional Paid-In Capital	Additional Paid-In Capital Performance-Based Restricted Stock Units (PSUs)	Additional Paid-In Capital Leveraged Stock Units (LSUs)	Additional Paid-In Capital Cumulative-effect adjustment from adoption of ASC 2020-06	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Retained Earnings (Accumulated Deficit) Cumulative-effect adjustment from adoption of ASC 2020-06	Treasury Stock
Beginning balance (in shares) at Dec. 31, 2021					90,759,000
Beginning balance at Dec. 31, 2021	$ 693,633			$ (66,383)	$ 908			$ 1,340,989			$ (106,172)	$ (362)	$ (626,779)	$ 39,789	$ (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	12,358							12,358
Exercise of stock options (in shares)					37,000
Exercise of stock options	309							309
Restricted stock units vested, net of shares withheld for taxes (in shares)					403,000
Restricted stock units vested, net of shares withheld for taxes	(5,239)				$ 4			(5,243)
Stock units vested, net of shares withheld for taxes (in shares)					458,000
Stock units vested, net of shares withheld for taxes	(11,232)				$ 4			(11,236)
Foreign currency translation adjustment	(420)											(420)
Net loss attributable to common shareholders of Evolent Health, Inc.	(9,938)												(9,938)
Ending balance (in shares) at Jun. 30, 2022					91,657,000
Ending balance at Jun. 30, 2022	613,088				$ 916			1,231,005				(782)	(596,928)		(21,123)
Beginning balance (in shares) at Mar. 31, 2022					91,588,000
Beginning balance at Mar. 31, 2022	611,209				$ 916			1,224,250				(494)	(592,340)		(21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	7,011							7,011
Restricted stock units vested, net of shares withheld for taxes (in shares)					69,000
Restricted stock units vested, net of shares withheld for taxes	(256)							(256)
Foreign currency translation adjustment	(288)											(288)
Net loss attributable to common shareholders of Evolent Health, Inc.	(4,588)												(4,588)
Ending balance (in shares) at Jun. 30, 2022					91,657,000
Ending balance at Jun. 30, 2022	$ 613,088				$ 916			1,231,005				(782)	(596,928)		(21,123)
Beginning balance (in shares) at Dec. 31, 2022	0
Beginning balance at Dec. 31, 2022	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of series A preferred stock, net of issuance costs (in shares)	175,000
Issuance of series A preferred stock, net of issuance costs	$ 168,000
Net loss attributable to common shareholders of Evolent Health, Inc.	$ 4,829
Ending balance (in shares) at Jun. 30, 2023	175,000
Ending balance at Jun. 30, 2023	$ 172,829
Beginning balance (in shares) at Dec. 31, 2022					101,501,000
Beginning balance at Dec. 31, 2022	859,417				$ 1,015			1,486,857				(1,178)	(606,154)		(21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	19,676							19,676
Exercise of stock options (in shares)					776,000
Exercise of stock options	4,654				$ 8			4,646
Restricted stock units vested, net of shares withheld for taxes (in shares)					492,000
Restricted stock units vested, net of shares withheld for taxes	(8,770)				$ 4			(8,774)
Stock units vested, net of shares withheld for taxes (in shares)						202,000	760,000
Stock units vested, net of shares withheld for taxes		$ (3,975)	$ 0			$ 2	$ 8		$ (3,977)	$ (8)
Shares issued for acquisition (in shares)					8,475,000
Shares issued for acquisition	261,271				$ 85			261,186
Class A common stock issued for payment of earn-outs (in shares)					877,000
Class A common stock issued for payment of earn-outs	28,551				$ 9			28,542
Foreign currency translation adjustment	64											64
Net loss attributable to common shareholders of Evolent Health, Inc.	(67,669)							(13,364)					(54,305)
Ending balance (in shares) at Jun. 30, 2023					113,083,000
Ending balance at Jun. 30, 2023	$ 1,093,219				$ 1,131			1,774,784				(1,114)	(660,459)		(21,123)
Beginning balance (in shares) at Mar. 31, 2023	175,000
Beginning balance at Mar. 31, 2023	$ 170,625
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to common shareholders of Evolent Health, Inc.	$ 2,204
Ending balance (in shares) at Jun. 30, 2023	175,000
Ending balance at Jun. 30, 2023	$ 172,829
Beginning balance (in shares) at Mar. 31, 2023					112,552,000
Beginning balance at Mar. 31, 2023	1,121,743				$ 1,125			1,768,999				(1,122)	(626,136)		(21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	8,966							8,966
Exercise of stock options (in shares)					446,000
Exercise of stock options	3,073				$ 5			3,068
Restricted stock units vested, net of shares withheld for taxes (in shares)					58,000
Restricted stock units vested, net of shares withheld for taxes	(138)							(138)
Class A common stock issued for payment of earn-outs (in shares)					27,000
Class A common stock issued for payment of earn-outs	978				$ 1			977
Foreign currency translation adjustment	8											8
Net loss attributable to common shareholders of Evolent Health, Inc.	(41,411)							(7,088)					(34,323)
Ending balance (in shares) at Jun. 30, 2023					113,083,000
Ending balance at Jun. 30, 2023	$ 1,093,219				$ 1,131			$ 1,774,784				$ (1,114)	$ (660,459)		$ (21,123)